Trea./Dir., Joseph Martin Piech, Secretary

American Transport Group, Inc., 4203 Americana Drive #104, Annandale, Virginia 22003, Officer: Elias T. Samaha, President

SEI Shipping Corporation, 1301 West Walnut Street, Compton, CA 90220, Officers: Pedro R. Garcia, President, Helen Park, Vice President/Sec./Trea., Yong Kyu Jun, Director of Operations

By the Federal Maritime Commission.

Dated: February 8, 1988.

Joseph C. Polking,

Secretary.

[FR Doc. 88-2865 Filed 2-10-88; 8:45 am]

BILLING CODE 6730-01-M

FEDERAL RESERVE SYSTEM

Bancorp New Jersey, Inc., et al.; Formations of; Acquisitions by; and Mergers of Bank Holding Companies

The companies listed in this notice have applied for the Board's approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) and § 225.14 of the Board's Regulation Y (12 CFR 225.14) to become a bank holding company or to acquire a bank or bank holding company. The factors that are considered in acting on the applications are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank or to the offices of the Board of Governors. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Unless otherwise noted, comments regarding each of these applications must be received not later than March 3, 1988.

A. **Federal Reserve Bank of New York** (William L. Rutledge, Vice President) 33 Liberty Street, New York, New York 10045:

1. *Bancorp New Jersey, Inc.*, Somerville, New Jersey; to become a bank holding company by acquiring 100 percent of the voting shares of New Jersey Savings Bank, Somerville, New Jersey.

B. **Federal Reserve Bank of Cleveland** (John J. Wixted, Jr., Vice President) 1455 East Sixth Street, Cleveland, Ohio 44101:

1. *Georgetown Bancorp, Inc.*, Georgetown, Kentucky; to become a bank holding company by acquiring 100 percent of the voting shares of Georgetown Bank & Trust Company, Georgetown, Kentucky, a de novo bank.

C. **Federal Reserve Bank of Atlanta** (Robert E. Heck, Vice President) 104 Marietta Street, NW., Atlanta, Georgia 30303:

1. *CeeBee Corporation*, Prattville, Alabama; to become a bank holding company by acquiring 80 percent of the voting shares of The Citizens Bank, Prattville, Alabama.

2. *Smoky Mountain Bancorp, Inc.*, Gatlinburg, Tennessee; to become a bank holding company by acquiring 100 percent of the voting shares of The First National Bank of Gatlinburg, Gatlinburg, Tennessee. Comments on this application must be received by February 26, 1988.

D. **Federal Reserve Bank of Chicago** (David S. Epstein, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. *Bath State Bancorp*, Bath, Indiana; to become a bank holding company by acquiring 100 percent of the voting shares of The Bath State Bank, Bath, Indiana. Comments on this application must be received by February 29, 1988.

E. **Federal Reserve Bank of St. Louis** (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63166:

1. *The Union of Arkansas Corporation*, Little Rock, Arkansas; to acquire at least 82 percent of the voting shares of Union National Bank of Arkansas, Magnolia, Arkansas.

Board of Governors of the Federal Reserve System, February 5, 1988.

James McAfee,

Associate Secretary of the Board.

[FR Doc. 88-2860 Filed 2-10-88; 8:45 am]

BILLING CODE 6210-01-M

Bankers Trust New York Corp.; Application To Engage de Novo in Permissible Nonbanking Activities

The company listed in this notice has filed an application under § 225.23(a)(1) of the Board's Regulation Y (12 CFR 225.23(a)(1)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to commence or to engage *de novo*, either directly or through a subsidiary, in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than February 25, 1988.

A. **Federal Reserve Bank of New York** (William L. Rutledge, Vice President) 33 Liberty Street, New York, New York 10045:

1. *Bankers Trust New York Corporation*, New York, New York; to engage *de novo* through its subsidiary, Texas and Southern Trust Company, Houston, Texas, in trust company functions pursuant to § 225.25(b)(3) of the Board's Regulation Y. These activities will be conducted in the State of Texas.

Board of Governors of the Federal Reserve System, February 5, 1988.

James McAfee,

Associate Secretary of the Board.

[FR Doc. 88-2861 Filed 2-10-88; 8:45am]

BILLING CODE 6210-01-M

First City Acquisition Corp., Formation of, Acquisition by, or Merger of Bank Holding Companies; and Acquisition of Nonbanking Company; Correction

This notice corrects a previous **Federal Register** notice (FR Doc. 88-2383) published at page 3454 of the issue for Friday, February 5, 1988.

Under the Federal Reserve Bank of Dallas, the entry for First City

Acquisition Corporation is revised to include the following:

A. **Federal Reserve Bank of Dallas** (W. Arthur Tribble, Vice President) 400 South Akard Street, Dallas, Texas 75222:

1. *First City Acquisition Corporation,* Houston, Texas; to acquire First City Bank, Sioux Falls, N.A., Sioux Falls, South Dakota, pursuant to section 4(c)(8) of the Bank Holding Company Act.

Comments on this application must be received by February 15, 1988.

Board of Governors of the Federal Reserve System, February 5, 1988.

James McAfee,

Associate Secretary of the Board.

[FR Doc. 88-2863 Filed 2-10-88; 8:45 am]

BILLING CODE 6210-01-M

First Eastern Corp.; Application To Engage de Novo in Permissible Nonbanking Activities

The company listed in this notice has filed an application under § 225.23(a)(1) of the Board's Regulation Y (12 CFR 225.23(a)(1)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to commence or to engage *de novo,* either directly or through a subsidiary, in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than March 3, 1988.

A. **Federal Reserve Bank of Philadelphia** (Thomas K. Desch, Vice President) 100 North 6th Street, Philadelphia, Pennsylvania 19105:

1. *First Eastern Corporation,* Wilkes-Barre, Pennsylvania; to engage *de novo* through its subsidiary, Dolphin and Bradbury, Inc., Philadelphia, Pennsylvania, in providing financial advice to state and local governments such as with respect to the issuance of their securities pursuant to § 225.25(b)(4)(v) of the Board's Regulation Y. These activities will be conducted in the Commonwealth of Pennsylvania.

Board of Governors of the Federal Reserve System, February 5, 1988.

James McAfee,

Associate Secretary of the Board.

[FR Doc. 88-2862 Filed 2-10-88; 8:45 am]

BILLING CODE 6210-01-M

GENERAL SERVICES ADMINISTRATION

Agency Information Collection Activities Under OMB Review

The GSA hereby gives notice under the Paperwork Reduction Act of 1980 that it is requesting the Office of Management and Budget (OMB) to renew expiring information collection 3090-0221, GSA Board of Contract Appeals Rules of Procedure.

AGENCY: Board of Contract Appeals, GSA.

ADDRESSES: Send comments to Bruce McConnell, GSA Desk Officer, Room 3235, NEOB, Washington, DC 20503, and to Mary L. Cunningham, GSA Clearance Officer, General Services Administration (CAIR), F Street at 18th NW., Washington, DC 20405.

Annual Reporting Burden: Firms responding, 1,520; responses, 1 per year; hours per response, varies; burden hours, 342.

Purpose: The Board of Contract Appeals requires the background information collected so that it will be properly informed to hold hearings on contract appeals and bid protests.

For Further Information Contact: Margaret S. Pfunder, Attorney-examiner, 202-566-0116.

Copy of Proposal: Readers may obtain a copy of the proposal by writing the Information Collection Management Branch (CAIR), Room 3014, GS Bldg., Washington, DC 20405, or by telephoning 202-535-7074.

Dated: February 2, 1988.

Emily C. Karam,

Director, Information Management Division (CAI).

[FR Doc. 88-2883 Filed 2-10-88; 8:45 am]

BILLING CODE 6820-34-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control

Conference on Quality Control Measures in Gynecologic Cytology

Action: Conference on Quality Control Measures in Gynecologic Cytology.

Time and Date: 8:00 a.m.—Tuesday, March 1, 1988, through 5:00 p.m.—Wednesday, March 2, 1988.

Place: Terrace Garden Inn, Pageantry Hall, 3405 Lenox Road, NE., Atlanta, Georgia 30326.

Status: Open to the Public for participation, comment, and observation, limited only by space available.

Purpose: The conference will provide a forum for professional organizations, Government agencies, and academic and clinical laboratories concerned with gynecologic cytology testing to present their current and future programs. Presentations and discussions during the conference will focus on (a) the status of the quality of Pap smear testing in the United States, (b) specific aspects of Pap smear testing which should be improved, (c) essential features of within-laboratory quality control and quality assurance of Pap smear testing, and (d) the appropriate mechanisms for external monitoring of laboratory performance of Pap smear testing.

Contact Person for More Information: Vernon N. Houk, M.D., Director, Center for Environmental Health and Injury Control, CDC, Atlanta, Georgia 30333. Telephones: FTS: 236-4111; Commercial: (404) 488-4111.

Dated: February 8, 1988.

Elvin Hilyer,

Associate Director for Policy Coordination, Centers for Disease Control.

[FR Doc. 88-2866 Filed 2-10-88; 8:45 am]

BILLING CODE 4160-18-M

Food and Drug Administration

[Docket No. 88F-0007]

Nutrasweet Co.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that the NutraSweet Co. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of aspartame as a sweetener in hot and instant cereals.

FOR FURTHER INFORMATION CONTACT: Joseph Leginus, Center for Food Safety and Applied Nutrition (HFF–334), Food and Drug Administration, 200 C Street SW., Washington, DC 20204, 202–426–5487.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 8A4055) has been filed by the NutraSweet Co., 4711 Golf Rd., Skokie, IL 60076, proposing that § 172.804 *Aspartame* (21 CFR 172.804) be amended to provide for the use of aspartame as a sweetener in hot and instant cereals.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: February 3, 1988.

Fred R. Shank,

Acting Deputy Director Center for Food Safety and Applied Nutrition.

[FR Doc. 88–2932 Filed 2–10–88; 8:45 am]

BILLING CODE 4160–01–M

[Docket No. 88M–0001]

NIDEK, Inc.; Premarket Approval of NIDEK ND:YAG Ophthalmic Laser Model YC–1000

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application by NIDEK, Inc., Palo Alto, California, for premarket approval, under the Medical Device Amendments of 1976, of the NIDEK Nd:YAG Ophthalmic Laser Model YC–1000. This laser is to be manufactured under an agreement with Allergan Medical Optics (AMO), Santa Ana, CA, which has authorized NIDEK, Inc., to include information based upon its approved premarket approval (PMA) application for the AMO Nd:YAG Ophthalmic Laser Model YAG–200. After reviewing the application from NIDEK, Inc., FDA's Center for Devices and Radiological Health (CDRH) notified the applicant of the approval of the application.

DATE: Petitions for administrative review by March 14, 1988.

ADDRESS: Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA–305), Food and Drug Administration, Rm. 4–62, 5600 Fishers Lane, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Robert A. Phillips, Center for Devices and Radiological Health (HFZ–460), Food and Drug Administration, 8757 Georgia Ave., Silver Spring, MD 20910, 301–427–8221.

SUPPLEMENTARY INFORMATION: On March 31, 1987, NIDEK, Inc., Palo Alto, CA 94303, submitted to CDRH an application for premarket approval of the NIDEK Nd:YAG Opthlamic Laser Model YC–1000. The neodymium:yttrium-aluminum-garnet (Nd:YAG) ophthalmic laser is identical to AMO Model YAG–200, indicated for the discission of the posterior capsule of the eye (posterior capsulotomy) and pupillary membranes (pupillary membranectomy) in aphakic and pseudophakic patients and performing iridotomy (hole in the iris) in phakic, pseudophakic and aphakic patients. The application included authorization from AMO, Santa Ana, CA 92799–5155, to include information based on its approved premarket approval application (PMA) and PMA supplements for AMO Model YAG–200 for the same indications.

On December 11, 1987, CDRH approved the application by a letter to the applicant from the Director of the Office of Device Evaluation, CDRH.

A summary of the safety and effectiveness data on which CDRH based its approval is on file in the Dockets Management Branch (address above) and is available from that office upon written request. Requests should be identified with the name of the device and the docket number found in brackets in the heading of this document.

A copy of all approved labeling is available for public inspection at CDRH—contact Robert A. Phillips, (HFZ–460), address above.

Opportunity for Administrative Review

Section 515(d)(3) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360e(d)(3)) authorizes any interested person to petition, under section 515(g) of the act (21 U.S.C. 360e(g)), for administrative review of CDRH's decision to approve this application. A petitioner may request either a formal hearing under Part 12 (21 CFR Part 12) of FDA's administrative practices and procedures regulations or a review of the application and CDRH's action by an independent advisory committee of experts. A petition is to be in the form of a petition for reconsideration under § 10.33(b) (21 CFR 10.33(b)). A petitioner shall identify the form of review requested (hearing or independent advisory committee) and shall submit with the petition supporting data and information showing that there is a genuine and substantial issue of material fact for resolution through administrative review. After reviewing the petition, FDA will decide whether to grant or deny the petition and will publish a notice of its decision in the Federal Register. If FDA grants the petition, the notice will state the issue to be reviewed, the form of review to be used, the persons who may participate in the review, the time and place where the review will occur, and other details.

Petitioners may, at any time on or before March 14, 1988, file with the Dockets Management Branch (address above) two copies of each petition and supporting data and information, identified with the name of the device and the docket number found in brackets in the heading of this document. Received petitions may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs. 515(d), 520(h), 90 Stat. 554–555, 571 (21 U.S.C. 360e(d), 360j(h)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Director, Center for Devices and Radiological Health (21 CFR 5.53).

Dated: February 2, 1988

John C. Villforth,

Director, Center for Devices and Radiological Health.

[FR Doc. 88–2934 Filed 2–10–88; 8:45 am]

BILLING CODE 4160–01–M

Public Health Service

Health Resources and Services Administration; Health Care Services in the Home, Part K of Title III of the Public Health Service Act; Delegation of Authority

Notice is hereby given that in furtherance of the delegation of authority to the Administrator, Health Resources and Services Administration